NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · XCRT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 01:32 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Xcelerate Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Xcelerate Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Xcelerate Inc. specializes in sourcing and integrating engineering expertise and patents, which it then applies to nascent medical technology ventures. The firm's offerings are subsequently deployed within regulated clinical settings for rigorous evaluation, validation, and real-world implementation. Beyond this, the company oversees a comprehensive, full-spectrum approach to medical technology creation and deployment. Established in 1996, the Mauldin, South Carolina-based entity was previously known as Union Dental Holdings, Inc. before rebranding as Xcelerate Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$5.73$0.00 (0.0%)
Selectis Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.72% below the high.
$0.25+$0.04 (+18.48%)
BioCorRx Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.47% below the high.
$1.94+$0.02 (+0.78%)
HealthLynked Corp.’s quoted price sits in the lower half of its reported 52-week range, 70.15% below the high.
$0.23-$0.02 (-7.86%)
20/20 Biolabs Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.54% below the high.
$0.00$0.00 (0.0%)
Ethema Health Corporation’s quoted price sits in the lower half of its reported 52-week range, 85.71% below the high.
